Nitric Oxide Gas Inhalation in Severe Acute Respiratory Syndrome in COVID-19
Status:
Active, not recruiting
Trial end date:
2022-12-21
Target enrollment:
Participant gender:
Summary
Severe acute respiratory syndrome (SARS-CoV2) due to novel Coronavirus (2019-nCoV) related
infection (COVID-19) is characterized by severe ventilation perfusion mismatch leading to
refractory hypoxemia. To date, there is no specific treatment available for 2019-nCoV. Nitric
oxide is a selective pulmonary vasodilator gas used in as a rescue therapy in refractory
hypoxemia due to acute respiratory distress syndrome (ARDS). In-vitro and clinical evidence
indicate that inhaled nitric oxide gas (iNO) has also antiviral activity against other
strains of coronavirus. The primary aim of this study is to determine whether inhaled NO
improves oxygenation in patients with hypoxic SARS-CoV2. This is a multicenter single-blinded
randomized controlled trial with 1:1 individual allocation
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico Niguarda Hospital Xijing Hospital